Citations

Showing 10 of 108152 citations.

Characteristics and Outcomes of Ventricular Tachycardia and Premature Ventricular Contractions Ablation in Patients with Prior Mitral Valve Surgery
Khalil, Fouad , Madhavan, Malini , Badawy, Mohammed, Kapa, Suraj , Mulpuru, Siva K. , Siontis, Konstantinos C. , DeSimone, Christopher V. , Deshmukh, Abhishek , Cha, Young-mei, Friedman, Paul A. , Munger, Thomas M. , Killu, Ammar M. , Khalil, Fouad , Kapa, Suraj , DeSimone, Christopher V , Toya, Takumi , Badawy, Mohammed, Asirvatham, Samuel J.

Mayo Clinic

No container title available | July 2, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.162524921.19356960/v1 Get It

Background: Data regarding ventricular tachycardia (VT) or premature ventricular complex (PVC) ablation following MVS is limited.) CA can be challenging given perivalvular substrate in the setting of mitral annuloplasty or prosthetic valves. Objective: To investigate the characteristics, safety, and outcomes of radiofrequency catheter ablation (CA) in patients with prior mitral valve surgery (MVS) and ventricular arrhythmias (VA). Methods: We identified consecutive patients with prior MVS who underwent CA for VT or PVC between January 2013- December 2018. We investigated the mechanism of arrhythmia, ablation approach, peri-operative complications, and outcomes. Results: In our cohort of 31 patients (77% men, mean age 62.3±10.8 years, left ventricular ejection fraction 39.2±13.9%) with prior MVS underwent CA (16 VT; 15 PVC). Access to the left ventricle was via transseptal approach in 17 patients, and a retrograde aortic approach was used in 13 patients. A combined transseptal and retrograde aortic approach was used in one patient, and a percutaneous epicardial approach was combined with trans-septal approach in 1patient. Heterogenous scar regions were present in 94% of VT patients and scar-related reentry was the dominant mechanism of VT. Clinical VA substrates involved the peri-mitral area in 6 patients with VT and 5 patients with PVC ablation. No procedure-related complications were reported. The overall recurrence-free rate at 1-year was 72.2%; 67% in the VT group and 78% in the PVC group. No arrhythmia-related death was documented on long-term follow-up. Conclusion: CA of VAs can be performed safely and effectively in patients with MVS
Laser Resurfacing Monotherapy for the Treatment of Actinic Keratosis
Tai, Felicia , Shah, Monica , Pon, Kucy, Alavi, Afsáneh , Alavi, A , Shah, Monica

Mayo Clinic

Journal of Cutaneous Medicine and Surgery | July 2, 2021 | Volume: 25 | Issue: 6 | Pages: 634-642

10.1177/12034754211027515 | PMID 34213956 Get It

Treating actinic keratosis (AK) and photodamaged skin is critical to reduce the risk of progression to skin cancer. Laser resurfacing for AK treatment is available as either lesion-directed or field therapy. Laser resurfacing removes the superficial epidermis and dermis containing actinic damage, promoting re-epithelialization of healthy skin. Although laser resurfacing has been explored as a modality for AK treatment in the literature, studies summarizing its efficacy in the treatment of AK are lacking. This review summarizes existing research on laser resurfacing as a monotherapy for AK treatment, highlighting the various laser resurfacing modalities available for AK treatment as well as their complications and efficacy in comparison to other therapies. Despite longer healing time, fully ablative laser resurfacing, including carbon dioxide and erbium-doped yttrium aluminum garnet were found to be more effective for AK treatment than fractional ablative techniques. Although some studies suggest laser resurfacing monotherapy as less efficacious than photodynamic therapy, and equally effective to 5-fluorouracil and 30% trichloroacetic acid, clinical trials of larger sample size are required to establish stronger evidence-based conclusions. Moreover, laser resurfacing used as lesion-directed therapy, as opposed to the usual field-therapy, requires further investigation.
Outcomes of Pericardiectomy for Constrictive Pericarditis following Mediastinal Irradiation
Pahwa, Siddharth , Miranda, William R. , Bernabei, Annalisa, Polycarpou, Andreas , Stulak, John M., Pochettino, Alberto , Daly, Richard C. , Lahr, Brian D. , Viehman, Jason K., Greason, Kevin L. , Crestanello, Juan A. , Schaff, Hartzell V. , Dearani, Joseph A.

Mayo Clinic

No container title available | July 2, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.162524764.48701825/v1 Get It

Background Pericardiectomy for post-radiation constrictive pericarditis has been reported to generally have unfavorable outcomes. This study sought to evaluate surgical outcomes in a large cohort of patients undergoing pericardiectomy for radiation-associated pericardial constriction. Methods A retrospective analysis of all patients (≥18years) who underwent pericardiectomy for a diagnosis of constrictive pericarditis with a prior history of mediastinal irradiation from June 2002 to June 2019 was conducted. There were 100 patients (mean age 57.2±10.1 years, 49% females) who met the inclusion criteria. Records were reviewed to look at surgical approach, extent of resection, early mortality and late survival. Results The overall operative mortality was 10.1% (n=10). The rate of operative mortality decreased over the study period; however, the test of trend was not statistically significant (P=0.062). Hodgkin’s disease was the most common malignancy (64%) for which mediastinal radiation had been received. Only 27% patients had an isolated pericardiectomy, and concomitant pericardiectomy and valve surgery was performed in 46% patients. Radical resection was performed in 50% patients, whereas 47% patients underwent a subtotal resection. Prolonged ventilation (26%), atrial fibrillation (21%) and pleural effusion (16%) were the most common post-operative complications. The overall 1,5- and 10-years survival was 73.6%, 53.4% and 32.1% respectively. Increasing age (HR 1.044, 95%CI 1.017-1.073) appeared to have a significant negative effect on overall survival in the univariate model. Conclusion Pericardiectomy performed for radiation associated constrictive pericarditis has poor long-term outcomes. The early mortality, though high (~10%), has been showing a decreasing trend in the test of time.
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy
Gustafson, Michael P. , Wheatley, Courtney M. , Gastineau, Dennis A. , Johnson, Bruce D. , Wheatley-Guy, Courtney M, Rosenthal, Allison C, Rosenthal, Allison , Katsanis, Emmanuel , Simpson, Richard J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 2, 2021 | Volume: 9 | Issue: 7 | Pages: e001872

10.1136/jitc-2020-001872 | PMID 34215686 Get It

The remarkable success of cancer immunotherapies has provided new hope to cancer patients. Unfortunately, a significant proportion of patients remain unable to respond to immunotherapy or maintain durable clinical responses. The lack of objective responses likely results from profound immune dysfunction often observed in patients with cancer. There is substantial evidence that exercise and physical activity can reduce incidence and improve outcomes in cancer patients. As the immune system is highly responsive to exercise, one potential avenue to improve immune function is through exercise and physical activity. A single event of dynamic exercise results in the substantial mobilization of leukocytes with increased functional capacities into the circulation. Chronic, or long-term, exercise leads to higher physical fitness in terms of greater cardiorespiratory function and/or muscle strength and endurance. High aerobic capacity, as measured by maximal oxygen uptake, has been associated with the reduction of dysfunctional T cells and improvements in the abundance of some T cell populations. To be sure, however, the mechanisms of exercise-mediated immune changes are both extensive and diverse. Here, we examine the evidence and theorize how acute and chronic exercise could be used to improve responses to cancer immunotherapies including immune checkpoint inhibitors, dendritic cell vaccines, natural killer cell therapies, and adoptive T cell therapies such as chimeric antigen receptor (CAR) T cells. Although the parameters of optimal exercise to yield defined outcomes remain to be determined, the available current data provide a compelling justification for additional human studies and clinical trials investigating the adjuvant use of exercise in immuno-oncology.
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Wen, Patrick Y. , Lim, Michael , Platten, Michael , Colman, Howard , Ashley, David M. , Chang, Susan M. , Mansouri, Alireza , Khagi, Simon , Heimberger, Amy B. , Reardon, David A. , Sahebjam, Solmaz , Simes, John, Antonia, Scott , Berry, Don, Tan, Aaron C. , Platten, Michael , Heimberger, Amy B. , Khasraw, Mustafa , Mansouri, Alireza , Bagley, Stephen , Wen, Patrick Yung , Colman, Howard , Wick, Wolfgang , Chang, Susan Marina , Galanis, Evanthia , Mehta, Minesh P. , Puduvalli, Vinay K. , Simes, Robert John , Berry, Donald A. , Khasraw, Mustafa

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 2, 2021 | Volume: 9 | Issue: 7 | Pages: e002459

10.1136/jitc-2021-002459 | PMID 34215688 Get It

With rapid advances in our understanding of cancer, there is an expanding number of potential novel combination therapies, including novel–novel combinations. Identifying which combinations are appropriate and in which subpopulations are among the most difficult questions in medical research. We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic review of trials of novel–novel combination therapies involving immunotherapies or molecular targeted therapies in advanced solid tumors. A MEDLINE search was conducted using a modified Cochrane Highly Sensitive Search Strategy for published clinical trials between July 1, 2017, and June 30, 2020, in the top-ranked medical and oncology journals. Trials were evaluated according to a criterion adapted from previously published Food and Drug Administration guidance and other key considerations in designing trials of combinations. This included the presence of a strong biological rationale, the use of a new established or emerging predictive biomarker prospectively incorporated into the clinical trial design, appropriate comparator arms of monotherapy or supportive external data sources and a primary endpoint demonstrating a clinically meaningful benefit. Of 32 identified trials, there were 11 (34%) trials of the novel–novel combination of anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) therapy, and 10 (31%) trials of anti-PD-1/PD-L1 and anti-vascular endothelial growth factor (VEGF) combination therapy. 20 (62.5%) trials were phase II trials, while 12 (37.5%) were phase III trials. Most (72%) trials lacked significant preclinical evidence supporting the development of the combination in the given indication. A majority of trials (69%) were conducted in biomarker unselected populations or used pre-existing biomarkers within the given indication for patient selection. Most studies (66%) were considered to have appropriate comparator arms or had supportive external data sources such as prior studies of monotherapy. All studies were evaluated as selecting a clinically meaningful primary endpoint. In conclusion, designing trials to evaluate novel–novel combination therapies presents numerous challenges to demonstrate efficacy in a comprehensive manner. A greater understanding of biological rationale for combinations and incorporating predictive biomarkers may improve effective evaluation of combination therapies. Innovative statistical methods and increasing use of external data to support combination approaches are potential strategies that may improve the efficiency of trial design. Designing trials to evaluate novel–novel combination therapies presents numerous challenges to demonstrate efficacy in a comprehensive manner. A greater understanding of biological rationale for combinations and incorporating predictive biomarkers may improve effective evaluation of combination therapies. Innovative statistical methods and increasing use of external data to support combination approaches are potential strategies that may improve the efficiency of trial design.
Transcatheter Tricuspid Valve Intervention: Current Perspective
Simard, Trevor , Eleid, Mackram F. , Simard, Trevor J., Simard, Trevor

Mayo Clinic

US Cardiology Review | July 2, 2021 | Volume: 15 | Issue: No issue available | Pages: No page available

10.15420/usc.2020.26 | PMID 39720492 Get It

Tricuspid regurgitation (TR) adversely impacts both quality of life and long-term survival, which generates interest in therapeutic approaches to mitigate these effects. Historically, therapeutic options for TR were limited to surgical approaches, which are often complicated by significant morbidity and mortality in elderly patients with multiple comorbidities. This gap in therapeutic options led to the rapid evolution of transcatheter tricuspid valve intervention (TTVI), with a wide variety of approaches pursued and early results suggesting that TTVI improves clinical outcomes. Numerous strategies, including edge-to-edge repair, annular reduction, spacers, caval valve implantation, and transcatheter tricuspid valve replacement form the basis of TTVI today. In this review, the authors discuss the current state of each approach.
Translating2019 ACSMCancer Exercise Recommendations for a Physiatric Practice: Derived Recommendations from an International Expert Panel
Parke, Sara C. , Ng, Amy , Martone, Patrick , Gerber, Lynn H. , Zucker, David S., Engle, Jessica , Gupta, Ekta , Power, Katherine, Sokolof, Jonas, Shahpar, Samman , Bagay, Leslie, Becker, Bruce E. , Langelier, David M. , Langelier, David Michael , Gerber, Lynn H , Parke, Sara C

Mayo Clinic

PM&R | July 2, 2021 | Volume: 14 | Issue: 8 | Pages: 996-1009

10.1002/pmrj.12664 | PMID 34213826 Get It

AbstractIn 2018, the American College of Sports Medicine (ACSM) reconvened an international, multi‐disciplinary group of professionals to review pertinent published literature on exercise for people with cancer. The 2018 roundtable resulted in the publication of three articles in 2019. The three articles serve as an important update to the original ACSM Roundtable on Cancer, which convened in 2010. Although the focus of the three 2019 articles is on exercise, which is only one part of comprehensive cancer rehabilitation, the evidence presented in the 2019 ACSM articles has direct implications for physiatrists and other rehabilitation professionals who care for people with cancer. As such, the narrative review presented here has two primary objectives. First, we summarize the evidence within the three ACSM articles and interpret it within a familiar rehabilitation framework, namely the Dietz model of Cancer Rehabilitation, in order to facilitate implementation broadly within rehabilitation practice. Second, via expert consensus, we have tabulated relevant exercise recommendations for specific cancer populations at different points in the cancer care continuum and translated them into text, tables, and figures for ease of reference. Notably, the authors of this article are members of the Cancer Rehabilitation Physician Consortium (CRPC), a group of physicians who subspecialize in cancer rehabilitation medicine (CRM).
Epigenetically Mediated Ciliogenesis and Cell Cycle Regulation, and Their Translational Potential
Li, Xiaoyan , Li, Linda Xiaoyan , Li, Xiaogang

Mayo Clinic

Cells | July 2, 2021 | Volume: 10 | Issue: 7 | Pages: 1662

10.3390/cells10071662 | PMID 34359832 Get It

Primary cilia biogenesis has been closely associated with cell cycle progression. Cilia assemble when cells exit the cell cycle and enter a quiescent stage at the post-mitosis phase, and disassemble before cells re-enter a new cell cycle. Studies have focused on how the cell cycle coordinates with the cilia assembly/disassembly process, and whether and how cilia biogenesis affects the cell cycle. Appropriate regulation of the functions and/or expressions of ciliary and cell-cycle-associated proteins is pivotal to maintaining bodily homeostasis. Epigenetic mechanisms, including DNA methylation and histone/chromatin modifications, are involved in the regulation of cell cycle progression and cilia biogenesis. In this review, first, we discuss how epigenetic mechanisms regulate cell cycle progression and cilia biogenesis through the regulation of DNA methylation and chromatin structures, to either promote or repress the transcription of genes associated with those processes and the modification of cytoskeleton network, including microtubule and actin. Next, we discuss the crosstalk between the cell cycle and ciliogenesis, and the involvement of epigenetic regulators in this process. In addition, we discuss cilia-dependent signaling pathways in cell cycle regulation. Understanding the mechanisms of how epigenetic regulators contribute to abnormal cell cycle regulation and ciliogenesis defects would lead to developing therapeutic strategies for the treatment of a wide variety of diseases, such as cancers, polycystic kidney disease (PKD), and other ciliopathy-associated disorders.
Instruction of Immunometabolism by Adipose Tissue: Implications for Cancer Progression
Raja, Remya , Wu, Christopher, Limbeck, Francesca, Butler, Kristina , Curtis, Marion , Curtis, Marion , Acharya, Abhinav P

Mayo Clinic

Cancers | July 2, 2021 | Volume: 13 | Issue: 13 | Pages: 3327

10.3390/cancers13133327 | PMID 34283042 Get It

Disruption of metabolic homeostasis at the organismal level can cause metabolic syndrome associated with obesity. The role of adipose tissue in cancer has been investigated over the last several decades with many studies implicating obesity as a risk factor for the development of cancer. Adipose tissue contains a diverse array of immune cell populations that promote metabolic homeostasis through a tightly controlled balance of pro- and anti-inflammatory signals. During obesity, pro-inflammatory cell types infiltrate and expand within the adipose tissue, exacerbating metabolic dysfunction. Some studies have now shown that the intracellular metabolism of immune cells is also deregulated by the lipid-rich environment in obesity. What is not fully understood, is how this may influence cancer progression, metastasis, and anti-tumor immunity. This review seeks to highlight our current understanding of the effect of adipose tissue on immune cell function and discuss how recent results offer new insight into the role that adipose tissue plays in cancer progression and anti-tumor immunity.
Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis
Kalinowska, Alicja , Tillema, Jan‐Mendelt , Tobin, W. Oliver , Guo, Yong , Fitz‐Gibbon, Patrick D., Weigand, Stephen D. , Giraldo‐Chica, Mónica , Lucchinetti, Claudia F. , Kalinowska-Lyszczarz, Alicja , Tobin, W Oliver , Port, John D.

Mayo Clinic

Multiple Sclerosis Journal | July 2, 2021 | Volume: 28 | Issue: 3 | Pages: 441-452

10.1177/13524585211024162 | PMID 34212755 Get It

Background: Limited studies have described long-term outcomes in pathology confirmed multiple sclerosis (MS). Objectives: To describe long-term clinical–radiographic–cognitive outcomes in a prospectively followed cohort of patients with pathologically confirmed CNS demyelinating disease, consistent with MS. Methods: Subjects underwent clinical assessment, standardized 3T-MRI brain, and cognitive battery. Results: Seventy-five patients were included. Biopsied lesion size was ⩾ 2 cm in 62/75. At follow-up, median duration since biopsy was 11 years. Median EDSS was 3 and lesion burden was large (median 10 cm 3 ). At follow-up, 57/75 met MS criteria, 17/75 had clinically isolated syndrome, and 1 radiographic changes only. Disability scores were comparable to a prevalence cohort in Olmsted County ( p < 0.001, n = 218). Cognitive outcomes below age-normed standards included psychomotor, attention, working memory, and executive function domains. Total lesion volume and index lesion-related severity correlated with EDSS and cognitive performance. Volumetric cortical/subcortical GM correlated less than lesion metrics to cognitive outcomes. Conclusion: Despite early aggressive course in pathologically confirmed MS, its long-term course was comparable to typical MS in our study. Cognitive impairment in this group seemed to correlate strongest to index lesion severity and total lesion volume. It remains to be established how the aggressive nature of the lesion, biopsy, and treatment affect clinical/cognitive outcomes.